Prestige Consumer Healthcare Inc. (PBH) — SEC Filings

Prestige Consumer Healthcare Inc. (PBH) — 21 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 6 10-Q, 5 SC 13G/A, 4 8-K.

View Prestige Consumer Healthcare Inc. on SEC EDGAR

Overview

Prestige Consumer Healthcare Inc. (PBH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Prestige Consumer Healthcare Inc. (PBH) reported a decline in net sales and net income for the three and six months ended September 30, 2025, compared to the prior year. For the three months, net sales decreased by 3.4% to $273,759 thousand from $283,548 thousand, and net income fell by 22.4% to $42

Sentiment Summary

Across 21 filings, the sentiment breakdown is: 2 bearish, 19 neutral. The dominant filing sentiment for Prestige Consumer Healthcare Inc. is neutral.

Filing Type Overview

Prestige Consumer Healthcare Inc. (PBH) has filed 6 10-Q, 2 DEF 14A, 2 10-K, 4 8-K, 5 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (21)

Prestige Consumer Healthcare Inc. SEC Filing History
DateFormDescriptionRisk
Nov 6, 202510-QPrestige Consumer Healthcare Sees Sales, Profit Dip Amid Economic Headwindshigh
Aug 7, 202510-QPrestige Consumer Healthcare Sees Stable Q1 Revenue, Boosted Retained Earningslow
Jun 27, 2025DEF 14ADEF 14A Filing
May 9, 202510-KPrestige Consumer Healthcare Files 2025 10-Kmedium
May 8, 20258-KPrestige Consumer Healthcare Files 8-K on Financialslow
Feb 6, 202510-QPrestige Consumer Healthcare Files 10-Q for Q3 2024medium
Jan 6, 20258-KPrestige Consumer Healthcare Files 8-K on Director Changes & Compensationlow
Nov 8, 2024SC 13G/ASC 13G/A Filing
Nov 7, 202410-QPrestige Consumer Healthcare Files Q2 2024 10-Qlow
Oct 18, 2024SC 13G/ASC 13G/A Filing
Aug 8, 202410-QPrestige Consumer Healthcare Files Q1 FY25 10-Qlow
Jul 5, 2024DEF 14APrestige Consumer Healthcare Proxy Statement Filedlow
May 15, 202410-KPrestige Consumer Healthcare Inc. Files 2024 Annual Reportlow
May 14, 20248-KPrestige Consumer Healthcare Files 8-Klow
May 8, 20248-KPrestige Consumer Healthcare Announces Executive and Board Changesmedium
Feb 14, 2024SC 13GSC 13G Filing
Feb 14, 2024SC 13GSC 13G Filing
Feb 13, 2024SC 13G/ASC 13G/A Filing
Feb 9, 2024SC 13G/ADimensional Fund Advisors Cuts Prestige Consumer Healthcare Stake to 12.6%medium
Feb 8, 202410-QPrestige Consumer Healthcare Inc. Files 10-Q for Period Ending December 31, 2023low

Risk Profile

Risk Assessment: Of PBH's 14 recent filings, 1 were flagged as high-risk, 4 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Prestige Consumer Healthcare Inc. Financial Summary (10-Q, Nov 6, 2025)
MetricValue
Revenue$273,759,000
Net Income$42,211,000
EPS$0.86
Cash Position$119,106,000
Total Assets$3,442,280,000
Total Debt$993,146,000

Key Executives

  • Dr. David R. Johnson
  • Ms. Jennifer L. Smith
  • Ms. Sarah M. Mook
  • Mr. Steven J. Gremban

Industry Context

Prestige Consumer Healthcare operates in the consumer healthcare sector, which is generally stable but sensitive to economic conditions and consumer spending habits. The industry faces ongoing challenges from supply chain disruptions, rising input costs, and increasing competition. Companies often rely on strong brand recognition and effective marketing to maintain market share.

Top Tags

10-Q (4) · financials (3) · Consumer Healthcare (2) · OTC Products (2) · 10-K (2) · healthcare (2) · financial-reporting (2) · 8-K (2) · company-update (2) · governance (2)

Key Numbers

Prestige Consumer Healthcare Inc. Key Metrics
MetricValueContext
Net Sales$273.8MDecreased 3.4% for the three months ended September 30, 2025, from $283.5M in 2024.
Net Income$42.2MDecreased 22.4% for the three months ended September 30, 2025, from $54.4M in 2024.
Diluted EPS$0.86Decreased from $1.09 for the three months ended September 30, 2024, to $0.86 in 2025.
Provision for Income Taxes$26.9MIncreased for the three months ended September 30, 2025, from $17.3M in 2024.
Treasury Share Repurchases$115.0MIncreased for the six months ended September 30, 2025, from $43.9M in 2024.
Cash and Cash Equivalents$119.1MIncreased from $97.9M at March 31, 2025, to September 30, 2025.
Product Revenue$277.5MSlight decrease from $280.0M in prior year, indicating stable demand.
North American OTC Healthcare Goodwill$1.36BConsistent goodwill reflects stable brand value and market position.
International OTC Healthcare Goodwill$120.0MMaintained goodwill indicates stable international brand strength.
Retained Earnings$1.04BIncreased from $1.02B, showing profitability and financial health.
Additional Paid-In Capital$1.10BIncreased from $1.09B, suggesting capital infusion or equity compensation.
Treasury Stock$1.03BDecreased from $1.04B, potentially indicating share repurchases.
Fiscal Year End2025-03-31End date of the reporting period
Filing Date2025-05-09Date the 10-K was submitted to the SEC
SEC File Number001-32433Identifies the company's filing history

Forward-Looking Statements

  • {"claim":"Prestige Consumer Healthcare Inc. stock may experience short-term selling pressure due to the reduction in institutional ownership.","entity":"Prestige Consumer Healthcare Inc.","targetDate":"3 months","confidence":"medium"}
  • {"claim":"Other institutional investors might review their positions in Prestige Consumer Healthcare Inc. following this filing.","entity":"Institutional Investors","targetDate":"6 months","confidence":"medium"}
  • {"claim":"Prestige Consumer Healthcare Inc. will continue to focus on managing its equity structure, potentially through share repurchases given the mention of 'Treasury Stock Common'.","entity":"Prestige Consumer Healthcare Inc.","targetDate":"2024-03-31","confidence":"medium"}

Related Companies

JNJ · PG · PCMH

Frequently Asked Questions

What are the latest SEC filings for Prestige Consumer Healthcare Inc. (PBH)?

Prestige Consumer Healthcare Inc. has 21 recent SEC filings from Jan 2024 to Nov 2025, including 6 10-Q, 5 SC 13G/A, 4 8-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of PBH filings?

Across 21 filings, the sentiment breakdown is: 2 bearish, 19 neutral. The dominant sentiment is neutral.

Where can I find Prestige Consumer Healthcare Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Prestige Consumer Healthcare Inc. (PBH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Prestige Consumer Healthcare Inc.?

Key financial highlights from Prestige Consumer Healthcare Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for PBH?

The investment thesis for PBH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Prestige Consumer Healthcare Inc.?

Key executives identified across Prestige Consumer Healthcare Inc.'s filings include Dr. David R. Johnson, Ms. Jennifer L. Smith, Ms. Sarah M. Mook, Mr. Steven J. Gremban.

What are the main risk factors for Prestige Consumer Healthcare Inc. stock?

Of PBH's 14 assessed filings, 1 were flagged high-risk, 4 medium-risk, and 9 low-risk.

What are recent predictions and forward guidance from Prestige Consumer Healthcare Inc.?

Recent forward-looking statements from Prestige Consumer Healthcare Inc. include guidance on {"claim":"Prestige Consumer Healthcare Inc. stock may experience short-term selling pressure due to the reduction in ins and 2 other predictions.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.